Other studies coming out of Europe have also found SB4 to work well for the majority of patients who switched from the originator etanercept.
Samsung Bioepis’ etanercept biosimilar, SB4, was effective and well-tolerated in the majority of patients who switched from originator etanercept (Enrel), according to a study from Poland.
The biosimilar is approved in a variety of European markets under the name Benepali. While it was approved by the FDA in April 2019, it has not yet launched here due to patent litigation. The anti-tumor necrosis factor (anti-TNF) inhibitor is currently prescribed in the United States for rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriatic arthritis (PsA), ankylosing spondylitis, and plaque psoriasis.
The observational study looked at patients being treated for RA, juvenile idiopathic arthritis, PsA, or ankylosing spondylitis, in which the originator etanercept replaced SB4.
Etanercept was replaced with SB4 in 162 patients (Group 1), and in another 6 patients SB4 was the initial biologic used (Group 2). Efficacy and safety were assessed over a 6-month period.
The biosimilar was effective and well-tolerated in the majority of patients. For 24 patients in Group 1 (14.8%), returning to Enbrel was necessary due to loss of efficacy or adverse events. Returning to the originator reversed the loss of efficacy or resolved the adverse event.
Previous observational studies have found rates of discontinuing the biosimilar ranging from 2% to 14%. In this study:
No adverse events were reported in the 6 patients for whom the biosimilar was the initial therapy (Group 2), and the biosimilar was effective in these patients.
Other studies coming out of Europe have also found SB4 to work well for the majority of patients who switched from the originator etanercept.
The authors conclude that SB4 was effective and well-tolerated in most patients, but that further research is required to investigate the effects of switching patients between originators and biosimilars.
Reference
Felis-Giemza A, Chmurzyńska K, Nałęcz-Janik J, et al. Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar. Reumatologia. 2019;57(5):257—263. doi:10.5114/reum.2019.89516.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More